A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19
Authors:
- Vincent DubéeVDVincent Dubée
- Pierre-Marie RoyPRPierre-Marie Roy
- Bruno VielleBVBruno Vielle
- Elsa Parot-SchinkelEPElsa Parot-Schinkel
- Odile BlanchetOBOdile Blanchet
- Astrid DarsonvalADAstrid Darsonval
- Caroline LefeuvreCLCaroline Lefeuvre
- Chadi AbbaraCAChadi Abbara
- Sophie BoucherSBSophie Boucher
- Edouard DevaudEDEdouard Devaud
- Olivier RobineauOROlivier Robineau
- Patrick RispalPRPatrick Rispal
Preprint
Abstract
Background: The efficacy of hydroxychloroquine in coronavirus disease 2019 (COVID-19) remains controversial. Methods: We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening: age ≥75 years, age between 60 and 74 years, and presence of at least one comorbidity, or need for supplemental oxygen (≤3 L/min). Eligible patients were randomized in a 1:1 ratio to receive either 800mg hydroxychloroquine on Day 0 followed by 400mg per day for 8 days or a placebo. The primary endpoint was a composite of death or tracheal intubation within 14 days following randomization. Secondary endpoints included mortality and clinical evolution at Day 14 and 28, viral shedding at Day 5 and 10. Results: The trial was stopped after 250 patients were included due to a slowdown of the pandemic in France. The intention-to-treat population comprised 123 and 124 patients in the placebo and hydroxychloroquine groups, respectively. The median age was 77 years and 151 patients required oxygen therapy. The primary endpoint occurred in nine patients in the hydroxychloroquine group and eight patients in the placebo group (relative risk 1.12; 95% confidence interval 0.45– 2.80; P=0.82). No difference was observed between the two groups in any of the secondary endpoints. Conclusion: In this trial involving mainly older patients with mild-to-moderate COVID-19, patients treated with hydroxychloroquine did not experience better clinical or virological outcomes than those receiving the placebo.Keywords
All Related Versions
- Published version: Clinical Microbiology and Infection, 27 (8), 1124.
This publication has 20 references indexed in Scilit:
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19New England Journal of Medicine, 2020
- Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19Annals of Internal Medicine, 2020
- Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled TrialClinical Infectious Diseases, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York StateJAMA, 2020
- Clinical and virological data of the first cases of COVID-19 in Europe: a case seriesThe Lancet Infectious Diseases, 2020
- Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trialBMJ, 2020
- Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatologyNature Reviews Rheumatology, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020